Novartis AG(NVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVS Novartis AG

Trading 05-14 12:44:28 EDT

103.13

+0.87

+0.85%

High103.39	Low102.74	Vol1.28M
Open102.74	D1 Closing102.26	Amplitude0.64%
Mkt Cap210.43B	Tradable Cap201.65B	Total Shares2.04B
T/O131.74M	T/O Rate0.07%	Tradable Shares1.96B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"Novartis AG","latestPrice":103.1311,"timestamp":1715705067893,"preClose":102.26,"halted":0,"volume":1278679,"delay":0,"floatShares":1955298792,"shares":2040406387,"eps":7.354219,"marketStatus":"Trading","change":0.8711,"latestTime":"05-14 12:44:28 EDT","open":102.74,"high":103.39,"low":102.74,"amount":131737451.17659001,"amplitude":0.006356,"askPrice":103.14,"askSize":75,"bidPrice":103.13,"bidSize":199,"shortable":3,"etf":0,"ttmEps":7.354219,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1715716800000},"marketStatusCode":2,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":102.26,"dividendRate":0.038,"preHourTrading":{"tag":"盘前","latestPrice":102.68,"preClose":102.26,"latestTime":"09:29 EDT","volume":9947,"amount":1022403.1907599999,"timestamp":1715693398070},"postHourTrading":{"tag":"盘后","latestPrice":102.26,"preClose":102.26,"latestTime":"18:57 EDT","volume":13796,"amount":1410766.22,"timestamp":1715641068708},"volumeRatio":1.924886},"requestUrl":"/m/hq/s/NVS/tweets","defaultTab":"tweets","newsList":[{"id":"2435710517","title":"Jeremy Grantham's Strategic Moves in Q1 2024: A Closer Look at Alphabet Inc's Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2435710517","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2435710517?lang=en_us&edition=fundamental","pubTime":"2024-05-14 23:01","pubTimestamp":1715698915,"startTime":"0","endTime":"0","summary":"Insights into Grantham's Latest 13F Filings and Portfolio Adjustments. Jeremy Grantham , the Chairman of the Board at Grantham Mayo van Otterloo  LLC, continues to influence the investment landscape with his strategic decisions. Known for his acute ability to identify and avoid market bubbles, Grantham's latest 13F filing for the first quarter of 2024 reveals significant transactions that underline his investment philosophy. His firm, based in Boston, is renowned for its expertise across various asset classes, including stocks, bonds, and commodities.GuruFocus has detected 5 Warning Sign with MSFT.United States Steel Corp , acquiring 861,481 shares, which now comprise 0.13% of the portfolio, valued at $35.13 million.McGrath RentCorp , with 264,563 shares, making up about 0.12% of the portfolio, valued at $32.64 million.GE HealthCare Technologies Inc , adding 300,328 shares, accounting for 0.1% of the portfolio, valued at $27.30 million.Grantham also strategically increased his stakes i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6Q2gnRcNNQgE.8OWu5Sv3w--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/fd7261e187c073f53b92cf6872bd4042","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6Q2gnRcNNQgE.8OWu5Sv3w--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/fd7261e187c073f53b92cf6872bd4042"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jeremy-granthams-strategic-moves-q1-150155261.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2435553546","title":"Q1 2024 Legend Biotech Corp Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2435553546","media":"Thomson Reuters StreetEvents","top":-1,"share":"https://ttm.financial/m/news/2435553546?lang=en_us&edition=fundamental","pubTime":"2024-05-14 12:20","pubTimestamp":1715660401,"startTime":"0","endTime":"0","summary":"Guowei Fang; Chief Scientific Officer & Head of Business Development; Legend Biotech Corporation. Steven J. Gavel; SVP of Commercial Development, US & Europe; Legend Biotech Corporation. Ying Huang; CEO & Director; Legend Biotech Corporation. Ashwani Verma; Director of Americas Equity Research & US Specialty Pharma Analyst; UBS Investment Bank, Research Division. Dingding Shi; Equity Analyst; Jefferies LLC, Research Division. Jessica Macomber Fye; Analyst; JPMorgan Chase & Co, Research Division. Justin Reid Zelin; Director & Biotechnology Research Analyst; BTIG, LLC, Research Division. Konstantinos Biliouris; Director & Biotechnology Analyst; BMO Capital Markets Equity Research. Umer Raffat; Senior MD & Senior Analyst of Equity Research; Evercore ISI Institutional Equities, Research Division. Yaron Benjamin Werber; MD & Senior Biotechnology Analyst; TD Cowen, Research Division. Good day, ladies and gentlemen. Thank you for standing by. Welcome to Legend Biotech First Quarter 2024 Finan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q1-2024-legend-biotech-corp-042001306.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435858307","title":"Voyager Therapeutics up 8% following quarterly beats","url":"https://stock-news.laohu8.com/highlight/detail?id=2435858307","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435858307?lang=en_us&edition=fundamental","pubTime":"2024-05-14 05:41","pubTimestamp":1715636492,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics is up ~8% in after-hour trading Monday after reporting Q1 financial results that beat on the top and bottom lines. In the quarter, the company swung to a loss of $11.3M from net income of ~$124M in the year-ago period. Net loss per share, diluted, was -$0.20 compared to $2.94 in Q1 2023.  Voyager was hurt in the quarter by an 87% year-over-year decline in collaboration revenue to ~$19.5M. In Q1 2023, the company received payments from Neurocrine Biosciences  as part of a collaboration agreement and from Novartis  for the exercise of capsid options. The company added that its current cash position of ~$400M is enough to fund operations through 2027. Voyager  noted that it received Investigational New Drug clearance from the U.S. FDA for anti-tau antibody VY-TAU01 for Alzheimer's with dosing of the first subject in a single ascending dose trial in healthy patients in the coming weeks.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186975279/image_186975279.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186975279/image_186975279.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105542-voyager-therapeutics-up-8-following-quarterly-beats","is_publish_highlight":false,"gpt_icon":0},{"id":"2434820211","title":"European buy-rated stocks that trade cheaply vs. their U.S. peers - UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2434820211","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434820211?lang=en_us&edition=fundamental","pubTime":"2024-05-11 22:00","pubTimestamp":1715436000,"startTime":"0","endTime":"0","summary":"UBS analysts list their best buy-rated European stocks that trade cheaply relative to their norm. These stocks are also considered to be superior compared to their U.S. peers.  Industrie De Nora SpA [","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1179363067/image_1179363067.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1179363067/image_1179363067.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104706-european-buy-rated-stocks-that-trade-cheaply-vs-their-us-peers-ubs","is_publish_highlight":false,"gpt_icon":0},{"id":"2434823774","title":"Tweedy, Browne Fund Q1 2024 Commentary","url":"https://stock-news.laohu8.com/highlight/detail?id=2434823774","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434823774?lang=en_us&edition=fundamental","pubTime":"2024-05-11 17:40","pubTimestamp":1715420400,"startTime":"0","endTime":"0","summary":"Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pens","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4692166-tweedy-browne-fund-q1-2024-commentary","is_publish_highlight":false,"gpt_icon":0},{"id":"2434831523","title":"3 Biotech Stocks to Sell in May Before They Crash & Burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2434831523","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2434831523?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:30","pubTimestamp":1715337000,"startTime":"0","endTime":"0","summary":"Which biotech stocks are not likely to pass through the gauntlet of financial fragility and innovation?Rallybio: This company continues to bleed money. Brief stock spikes onlyserve toremind investors that not even good news can absorb the drain.BenevolentAI: This is an example of what type of fundamentals to avoidwhen it comes tothe AI buzzwordplusdrugs.Typical for volatile penny stocks, Rallybio  rallied to $2.98 mid-April, only to fall down to its present $1.85 per share. But given its 52-week low of $1.23, that is still up 33%. Year-to-date, RLYB stock is down nearly 22%.Yet, as Rallybio failed to deliver a single profitable quarter since, its net losses steadily increased. For the fiscal year of 2023, the company reported this March that it will “continue to incur net losses and negative cash flows in the foreseeable future”. In total, R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/3-biotech-stocks-to-sell-in-may-before-they-crash-burn/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434835635","title":"Eurozone stocks are at their highest in 16 years. UBS now prefers Europe over U.S. equities.","url":"https://stock-news.laohu8.com/highlight/detail?id=2434835635","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434835635?lang=en_us&edition=fundamental","pubTime":"2024-05-10 17:47","pubTimestamp":1715334420,"startTime":"0","endTime":"0","summary":"The iShares MSCI Eurozone ETF EZU registered its highest close since June 2008, and other European benchmarks including the Stoxx Europe 600 XX:SXXP, the German DAX DX:DAX and U.K. FTSE 100 UK:UKX are at record levels.UBS strategists led by Andrew Garthwaite say they now prefer European stocks over their U.S. counterparts - though it should be said, to only the middle of its regional scorecard. Their top region is Japan, followed by the U.K., Europe ex-U.K., emerging markets and lastly the U.S.The first reason is that the soft economic data - mostly purchasing managers indexes - are now surprising positively in Europe, which leads the UBS team to think the near record GDP growth rate gap between the U.S. and Europe may close.Not only is the path to rate cuts much clearer for Europe, with their inflation data better behaved, but the benefit is stronger, because of the shorter maturity of European debt. And more limited wage growth impacts not just inflation but also corporate profit mar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2434097756","title":"Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired","url":"https://stock-news.laohu8.com/highlight/detail?id=2434097756","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434097756?lang=en_us&edition=fundamental","pubTime":"2024-05-09 21:14","pubTimestamp":1715260493,"startTime":"0","endTime":"0","summary":"Viking Therapeutics, a clinical-stage company focused on metabolic and endocrine disorders, is primed for acquisition due to its robust pipeline and potential as a market disruptor.The company's pipel","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767170790/image_1767170790.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1767170790/image_1767170790.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4691236-viking-therapeutics-the-metabolic-masterpiece-primed-to-be-acquired","is_publish_highlight":false,"gpt_icon":0},{"id":"2434177774","title":"IYH: How Another Smaller, Equally-Weighted Competitor May Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2434177774","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434177774?lang=en_us&edition=fundamental","pubTime":"2024-05-09 01:25","pubTimestamp":1715189120,"startTime":"0","endTime":"0","summary":"izusek/E+ via Getty Images Investment Thesis iShares U.S. Healthcare ETF (NYSEARCA:IYH) is a hold due to multiple near-term factors that will drag the fund downward. These headwinds include the high v","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1475020235/image_1475020235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1475020235/image_1475020235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4690793-iyh-etf-how-another-smaller-equally-weighted-competitor-may-outperform","is_publish_highlight":false,"gpt_icon":0},{"id":"2433433269","title":"Lantheus Holdings: Powerful First Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2433433269","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2433433269?lang=en_us&edition=fundamental","pubTime":"2024-05-05 21:45","pubTimestamp":1714916700,"startTime":"0","endTime":"0","summary":"Lantheus Holdings just posted strong Q1 numbers, exceeding expectations and confirming its attractive investment potential.The firm is delivering solid revenue growth, impressive free cash flow, and m","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/493216371/image_493216371.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/493216371/image_493216371.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688961-lantheus-holdings-powerful-first-quarter","is_publish_highlight":false,"gpt_icon":0},{"id":"2432184576","title":"Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2432184576","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432184576?lang=en_us&edition=fundamental","pubTime":"2024-05-04 00:29","pubTimestamp":1714753740,"startTime":"0","endTime":"0","summary":"The adjusted figure excluded items like stock-based compensation expenses and realized and unrealized  loss on marketable equity securities.Alnylam recorded total revenues of $494 million in the quarter, which surpassed the Zacks Consensus Estimate of $421 million. In the year-ago quarter, total revenues were $319 million. Net product revenues were $365 million, up 32% year over year on a reported basis, as well as at constant exchange rate, driven by increased patient numbers for Givlaari , Oxlumo  and the newly approved Amvuttra .Net revenues from collaborators were $119 million, up 225% from $36 million reported in the year-ago quarter. The uptick was primarily driven by revenues recognized under the company’s licensing agreement with Roche RHHBY, which included a $65 million milestone payment that Alnylam received upon dosing the first patient in the zilebesiran KARDIA-3 clinical study for hypertension indication.Year to date, shares of Alnylam have plunged 21.5% compared with thei","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/huDYWWooSs3LEZkYeanM9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c9aff063e0b66455eb97289290f920eb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/huDYWWooSs3LEZkYeanM9w--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c9aff063e0b66455eb97289290f920eb"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-alny-q1-loss-narrower-162900353.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432190243","title":"Swiss Helvetia Fund: High Yield, Quality Swiss Stocks At A Discount To Net Asset Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2432190243","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432190243?lang=en_us&edition=fundamental","pubTime":"2024-05-03 23:15","pubTimestamp":1714749329,"startTime":"0","endTime":"0","summary":"The market tends to overlook and undervalue closed-end funds, and many investors simply ignore them. Sometimes, it can be the case that closed-end funds are actually able to deliver higher returns than open-ended funds, so it is good to not write off the sector entirely. In more concentrated funds, like the Swiss Helvetia Fund, the overall performance becomes correlated to just a handful of stocks, which can end up being a blessing or a curse. This can be a drag on returns if underperformance of the largest holdings weighs down the fund, but it can also decrease volatility and offer investors more time to accumulate shares and reinvest dividends at opportune moments. SWZ 5-Year Chart  With prices near the mid $7 range, I think that SWZ could be approaching buy territory sooner rather than later. In this article, I will take a deeper look into the holdings and explain the discount to NAV, the high dividend nature of the","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172514465/image_172514465.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172514465/image_172514465.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4689072-swiss-helvetia-fund-high-yield-quality-swiss-stocks-at-a-discount","is_publish_highlight":false,"gpt_icon":0},{"id":"2432031269","title":"TG Therapeutics: Less Room For Doubt About Briumvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2432031269","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432031269?lang=en_us&edition=fundamental","pubTime":"2024-05-03 21:53","pubTimestamp":1714744435,"startTime":"0","endTime":"0","summary":"TG Therapeutics beat first quarter revenue expectations and raised the full-year revenue guidance by $40 million at the mid-point.Work on the subcutaneous version of Briumvi continues and could repres","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227304809/image_1227304809.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227304809/image_1227304809.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4689034-tg-therapeutics-less-room-for-doubt-about-briumvi","is_publish_highlight":false,"gpt_icon":0},{"id":"2432927658","title":"10 Sleep-Well-At-Night Dividend Aristocrats Perfect For Whatever's Coming Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2432927658","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432927658?lang=en_us&edition=fundamental","pubTime":"2024-05-03 19:00","pubTimestamp":1714734000,"startTime":"0","endTime":"0","summary":"Safe Investing: Simple In Theory, Challenging In Practice Ritholtz Wealth management  Stocks are the best-performing asset in history, delivering 2.4 million X inflation-adjusted returns since 1802. Ben Carlson The worst 30-year return since 1926 was 1929's pre-Great Depression bubble top to 1959. That 30-year rolling return was 7.8%. Allow me to repeat that stat for the people in the back — the worst 30-year return over the past 100 years or so was a total gain of 850%.\" - Wealth Of Common Sense  By the way, 1938 to 1968 was the best 30-year return, 14.8% annually for three decades or 6,184% gain, turning $1 into $62.84. On average, investors could double their money every five years for 30 years. Such was the bearishness and l","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291620275/image_1291620275.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291620275/image_1291620275.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688064-10-dividend-aristocrats-perfect-for-whatevers-coming-next","is_publish_highlight":false,"gpt_icon":0},{"id":"2432258029","title":"Veeva Systems: Stellar Growth And Profitability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2432258029","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432258029?lang=en_us&edition=fundamental","pubTime":"2024-05-03 17:18","pubTimestamp":1714727894,"startTime":"0","endTime":"0","summary":"Veeva Systems is an under-the-radar stock with impressive revenue growth and profitability in the life sciences software industry.The company's business model relies on subscription revenues, providing opportunities for cross-selling and high retention rates.VEEV holds around 16% of the global life sciences software market and has a more efficient and scalable business model compared to the industry's biggest name, IQVIA.Michael Vi My thesis Veeva Systems  appears to be an under-the-radar stock, which is unfair because of the company's stellar revenue growth history coupled with impressive profitability profile. The company's revenue growth outpaces the industry leader by a wide margin, which likely indicates that VEEV is a disruptor in the life sciences software industry. Indeed, the business model looks modern as it mostly relies on revenues from subscriptions and provides VEEV solid opportunities to \"land and expand\" to cross-sell its various modules across its cloud-based SaaS offe","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551564/image_1181551564.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551564/image_1181551564.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688968-veeva-systems-stellar-growth-profitability-profile","is_publish_highlight":false,"gpt_icon":0},{"id":"2432316499","title":"Radiopharma stocks higher as sector welcomes the latest M&A deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2432316499","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432316499?lang=en_us&edition=fundamental","pubTime":"2024-05-03 02:31","pubTimestamp":1714674710,"startTime":"0","endTime":"0","summary":"Shares of radiopharma companies spiked Thursday as investors welcomed the latest M&A deal to hit the sector, this time between Swiss pharma giant Novartis (NYSE:NVS) and preclinical-stage biotech Mari","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2050067813/image_2050067813.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2050067813/image_2050067813.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099035-novartis-mariana-oncology-deal-drives-radiopharma","is_publish_highlight":false,"gpt_icon":0},{"id":"2432984759","title":"Harrow: Merits A Buy On Sales Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2432984759","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432984759?lang=en_us&edition=fundamental","pubTime":"2024-05-03 00:20","pubTimestamp":1714666824,"startTime":"0","endTime":"0","summary":"Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound.Iheezo, an ocular anesthetic, has a substantial market opportunity and is expecte","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688507-harrow-merits-a-buy-on-sales-potential","is_publish_highlight":false,"gpt_icon":0},{"id":"2432198087","title":"Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat","url":"https://stock-news.laohu8.com/highlight/detail?id=2432198087","media":"MT Newswires","top":-1,"share":"https://ttm.financial/m/news/2432198087?lang=en_us&edition=fundamental","pubTime":"2024-05-02 23:54","pubTimestamp":1714665267,"startTime":"0","endTime":"0","summary":"All three major US indexes were trading in positive territory late Thursday morning as investors digest the Federal Open Market Committee's Wednesday announcement to hold rates steady and prepare for a crucial jobs report Friday.Linde  reported Q1 adjusted EPS Thursday of $3.75, up from $3.42 a year before and above the Capital IQ consensus analyst estimate of $3.67. First-quarter sales were $8.10 billion, down from $8.19 billion last year and below the Capital IQ consensus analyst estimate of $8.38 billion. The company is forecasting Q2 adjusted EPS of between $3.70 and $3.80, under the Capital IQ consensus analyst forecast of $3.90. For full-year 2024, Linde anticipates adjusted EPS of between $15.30 and $15.60, compared to its prior guidance range of $15.25 to $15.65. Analysts polled by Capital IQ expect $15.55. Linde shares were down 6.2%.Peloton  announced Thursday that it is cutting its global headcount by about 15%, affecting nearly 400 employees. The company also said Chief Exe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-midday-stories-novo-nordisk-155427452.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432674689","title":"Novartis to buy Mariana Oncology for $1B upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2432674689","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432674689?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:46","pubTimestamp":1714650381,"startTime":"0","endTime":"0","summary":"Novartis (NYSE:NVS) has agreed to acquire cancer drugmaker Mariana Oncology for an upfront payment of $1B and an additional $750M in milestone payments. The transaction, subject to customary closing c","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458292255/image_458292255.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458292255/image_458292255.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098400-novartis-to-buy-mariana-oncology-for-1b-upfront","is_publish_highlight":false,"gpt_icon":0},{"id":"2432034556","title":"UPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2432034556","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432034556?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:30","pubTimestamp":1714649427,"startTime":"0","endTime":"0","summary":"The deal includes up to $750 million of further payments upon achieving certain milestones, it added.Mariana Oncology is working on novel radioligand cancer therapies  that have not yet been tested on humans.\"The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities,\" Novartis said in a statement.Radioligand therapy, based on cell-killing radioactive particles that are attached to tumour-seeking molecules, is one of three technologies that Novartis' development efforts are focused on, apart from cell and gene therapy as well as RNA.The Swiss group's radioligand drugs include Pluvicto against prostate cancer and Lutathera against a rare group of gastrointestinal tumours.Novartis has been cutting jobs and costs, and spun off its generic drugs business Sandoz last year, part of a focus on fewer therapeutic areas and geographic markets.In February, it struck a deal to buy German cancer drug developer MorphoSys for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/2-novartis-buy-radiology-drug-113027745.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":0.0464},{"period":"1month","weight":0.0935},{"period":"3month","weight":0.0323},{"period":"6month","weight":0.0902},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":0.0128}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0543},{"period":"6month","weight":0.1584},{"period":"1year","weight":0.2656},{"period":"ytd","weight":0.0959}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.014981},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.012188},{"month":3,"riseRate":0.5,"avgChangeRate":0.000575},{"month":4,"riseRate":0.708333,"avgChangeRate":0.018746},{"month":5,"riseRate":0.666667,"avgChangeRate":0.008431},{"month":6,"riseRate":0.541667,"avgChangeRate":0.009763},{"month":7,"riseRate":0.708333,"avgChangeRate":0.012897},{"month":8,"riseRate":0.375,"avgChangeRate":-0.006962},{"month":9,"riseRate":0.708333,"avgChangeRate":0.011946},{"month":10,"riseRate":0.458333,"avgChangeRate":-0.010373},{"month":11,"riseRate":0.625,"avgChangeRate":0.016564},{"month":12,"riseRate":0.708333,"avgChangeRate":0.0233}],"exchange":"NYSE","name":"Novartis AG","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Novartis AG(NVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Novartis AG(NVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Novartis AG,NVS,Novartis AG股票,Novartis AG股票老虎,Novartis AG股票老虎国际,Novartis AG行情,Novartis AG股票行情,Novartis AG股价,Novartis AG股市,Novartis AG股票价格,Novartis AG股票交易,Novartis AG股票购买,Novartis AG股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Novartis AG(NVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Novartis AG(NVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction